Dong-A ST announced on October 11 that it will present a poster on the research results of its Src homology phosphatase-1 (SHP1)-targeted immuno-oncology drug candidate "DA-4511" at "AACR-NCI-EORTC 2023" to be held from October 11 to 15 in Boston, Massachusetts, USA.
AACR-NCI-EORTC is an international conference jointly organized by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC) that rotates annually between the United States and Europe. Experts in the field of cancer research and industry from around the world gather to discuss various issues related to cancer treatment and new drugs.
On October 14, Dong-A ST will present a poster on "Anti-Cancer Immunotherapeutic Effects of a First-in-Class SHP1 Inhibitor and Synergy with Immune Checkpoint Inhibitor PD-1 Antibody" on DA-4511 at the AACR-NCI-EORTC meeting.
The presentation will include data on DA-4511's ability to increase cytokine secretion and promote cytotoxicity in immune cells, as well as its anti-cancer effects in animal models and synergistic effects when co-administered with existing immune checkpoint inhibitor PD-1 antibodies.
By identifying allosteric sites that can selectively inhibit SHP1, Dong-A ST succeeded in discovering small molecules that can be taken orally.
These findings confirm the potential of DA-4511 as the world's first SHP1 allosteric inhibitor and a novel immuno-oncology drug.
